Belite Bio Net Worth
Belite Bio Net Worth Breakdown | BLTE |
Belite Bio Net Worth Analysis
Belite Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Belite Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Belite Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Belite Bio's net worth analysis. One common approach is to calculate Belite Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Belite Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Belite Bio's net worth. This approach calculates the present value of Belite Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Belite Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Belite Bio's net worth. This involves comparing Belite Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Belite Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Belite Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Belite Bio's net worth research are outlined below:
| Belite Bio ADR appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (31.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Belite Bio ADR currently holds about 48.7 M in cash with (29.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.96. | |
| Belite Bio ADR has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 |
Belite Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Belite Bio ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Belite Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Belite Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Belite Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Belite Bio ADR backward and forwards among themselves. Belite Bio's institutional investor refers to the entity that pools money to purchase Belite Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-06-30 | 88.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 8.0 | Marshall Wace Asset Management Ltd | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | State Street Corp | 2024-06-30 | 15.7 K | Geode Capital Management, Llc | 2024-09-30 | 6.7 K | Citadel Advisors Llc | 2024-09-30 | 6.5 K | Hrt Financial Llc | 2024-06-30 | 5.4 K | Xtx Topco Ltd | 2024-09-30 | 5.4 K | Point72 Asset Management, L.p. | 2024-09-30 | 4.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 K |
Follow Belite Bio's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.08 B.Market Cap |
|
Project Belite Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.35) | (0.33) |
When accessing Belite Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Belite Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Belite Bio's profitability and make more informed investment decisions.
Please note, the presentation of Belite Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Belite Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Belite Bio's management manipulating its earnings.
Evaluate Belite Bio's management efficiency
Belite Bio ADR has return on total asset (ROA) of (0.2558) % which means that it has lost $0.2558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4004) %, meaning that it created substantial loss on money invested by shareholders. Belite Bio's management efficiency ratios could be used to measure how well Belite Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, Belite Bio's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.04, whereas Net Tangible Assets are forecasted to decline to (14.3 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.40 | 3.57 | |
| Tangible Book Value Per Share | 3.28 | 3.44 | |
| Enterprise Value Over EBITDA | (35.82) | (37.61) | |
| Price Book Value Ratio | 13.45 | 14.13 | |
| Enterprise Value Multiple | (35.82) | (37.61) | |
| Price Fair Value | 13.45 | 14.13 | |
| Enterprise Value | 504.9 M | 291.2 M |
Understanding the operational decisions made by Belite Bio management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Return On Equity (0.40) |
Belite Bio Corporate Filings
6K | 4th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 1st of October 2024 Other Reports | ViewVerify | |
| 29th of April 2024 Other Reports | ViewVerify | |
13A | 12th of February 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Belite Bio Earnings per Share Projection vs Actual
Belite Bio Corporate Management
| ChingChen MSc | VP Operations | Profile | |
| YuHsin MBA | Chairman CEO | Profile | |
| CFA FRM | CFO Director | Profile | |
| MA MD | Chief Board | Profile | |
| Nathan Mata | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Belite Bio ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Belite Bio. If investors know Belite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Belite Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (0.26) | Return On Equity (0.40) |
The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Belite Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Belite Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Belite Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.